IPF is a lethal disease leading to death by suffocation due to the relentless accumulation of fibroblasts and their connective tissue products in the alveolar wall. As each alveolus is afflicted by the disease process, there is a pernicious collaboration of innate immunity, epithelial cell death and fibroproliferation simulating the events observed in injury -- except in IPF the injury never heals. In an effort to arrest this progressive disease, here we focus on the fibroproliferative process itself, and its key cellular constituent the myofibroblast. One striking difference between myofibroblasts from fibrotic lesions and those from integumentary and visceral wounds that heal normally is the failure of fibrotic myofibroblasts - in contrast to their normal counterparts - to undergo timely apoptosis. Therefore, we hypothesize that regulatory constituents of the apoptotic cascade that result in aberrant myofibroblast persistence will be candidate molecular targets for antifibrotic drug discovery. Our objective is to develop therapeutics designed to undermine the pathological failure of myofibroblasts in the IPF lung to undergo apoptosis, and restore physiological sensitivity to proapoptotic cues in evolving fibrotic lesions. We plan to achieve our objective through 2 specific aims.
Aim 1 : Synthesize and evaluate compounds hitting the cap-binding pocket of eukaryotic translation initiation factor 4E (eIF4E), a bonafide molecular target controlling the translation of mRNA encoding key regulators of fibroblast apoptosis.
Aim 2 : Explore potential molecular targets for antifibrotic drug discovery along apoptotic pathways regulated by the extracellular matrix. If successful, our work will confirm or refute eIF4E as an antifibrotic therapeutic target, and potentially lead to the identification of new IPF specific molecular targets for antifibrotic drug discovery.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL073719-01
Application #
6663549
Study Section
Special Emphasis Panel (ZHL1-CSR-P (M1))
Program Officer
Reynolds, Herbert Y
Project Start
2003-09-01
Project End
2007-06-30
Budget Start
2003-09-01
Budget End
2004-06-30
Support Year
1
Fiscal Year
2003
Total Cost
$740,767
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Fan, Danhua; Bitterman, Peter B; Larsson, Ola (2009) Regulatory element identification in subsets of transcripts: comparison and integration of current computational methods. RNA 15:1469-82
Larsson, Ola; Diebold, Deanna; Fan, Danhua et al. (2008) Fibrotic myofibroblasts manifest genome-wide derangements of translational control. PLoS One 3:e3220
Ghosh, Phalguni; Cheng, Jilin; Chou, Tsui-Fen et al. (2008) Expression, purification and characterization of recombinant mouse translation initiation factor eIF4E as a dihydrofolate reductase (DHFR) fusion protein. Protein Expr Purif 60:132-9
Xia, Hong; Diebold, Deanna; Nho, Richard et al. (2008) Pathological integrin signaling enhances proliferation of primary lung fibroblasts from patients with idiopathic pulmonary fibrosis. J Exp Med 205:1659-72
Vlasova, Irina A; Tahoe, Nuzha M; Fan, Danhua et al. (2008) Conserved GU-rich elements mediate mRNA decay by binding to CUG-binding protein 1. Mol Cell 29:263-70
Chou, Tsui-Fen; Baraniak, Janina; Kaczmarek, Renata et al. (2007) Phosphoramidate pronucleotides: a comparison of the phosphoramidase substrate specificity of human and Escherichia coli histidine triad nucleotide binding proteins. Mol Pharm 4:208-17
Larsson, Ola; Li, Shunan; Issaenko, Olga A et al. (2007) Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors. Cancer Res 67:6814-24
Jacobson, Blake A; Alter, Michael D; Kratzke, Marian G et al. (2006) Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo. Cancer Res 66:4256-62
Larsson, Ola; Perlman, David M; Fan, Danhua et al. (2006) Apoptosis resistance downstream of eIF4E: posttranscriptional activation of an anti-apoptotic transcript carrying a consensus hairpin structure. Nucleic Acids Res 34:4375-86
Avdulov, Svetlana; Li, Shunan; Michalek, Van et al. (2004) Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 5:553-63

Showing the most recent 10 out of 11 publications